It's a wild guess at best regarding the share price and near term success in COVID. I agree that the hype will make it blast off, but the factors you mention have to be considered when estimating the long term revenues/value. I could absolutely see a scenario where we go to $10+ with approval, then have that cut in half rather quickly as competition develops in the space. It sure would be nice to have that money to fund these other trials where the real potential of this drug lies.